Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Active, not recruiting2
Enrolling by invitation1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

enrolling_by_invitation125%
not_yet_recruiting125%
active_not_recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
not_yet_recruitingphase_1

Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)

NCT07423494
active_not_recruitingphase_1

Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS

NCT06392126
enrolling_by_invitationphase_1

Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS

NCT07095686
active_not_recruitingphase_1

Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS

NCT06977451

Clinical Trials (4)

Showing 4 of 4 trials
NCT07423494Phase 1

Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)

Not Yet Recruiting
NCT06392126Phase 1

Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS

Active Not Recruiting
NCT07095686Phase 1

Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS

Enrolling By Invitation
NCT06977451Phase 1

Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4